
Evacetrapib appears futile in high-risk vascular disease
(HealthDay)—For patients with high-risk vascular disease, evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes, myocardial infarction, ...
May 31, 2017
0
0